Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- Registration Number
- NCT04666038
- Lead Sponsor
- Loxo Oncology, Inc.
- Brief Summary
This is a study for patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have previously received treatment with at least a BTK inhibitor. The main purpose is to compare LOXO-305 to idelalisib plus rituximab or bendamustine plus rituximab. Participation could last up to four years, and possibly longer, if the disease does not progress.
- Detailed Description
This is a Phase 3 global, randomized, open-label study comparing LOXO-305 (Arm A) to investigator's choice of either idelalisib plus rituximab or bendamustine plus rituximab (Arm B) in CLL/SLL patients who have been treated with at least a covalent BTK inhibitor (BTKi). Patients may have discontinued the prior covalent BTKi due to disease progression (PD) or intolerance. Patients who have received venetoclax are eligible for the study. Eligible patients will be randomized in 1:1 to Arm A or Arm B.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 238
- Confirmed diagnosis of CLL/SLL requiring therapy as defined by iwCLL 2018 criteria.
- Previously treated with a covalent BTK inhibitor.
- Eastern Cooperative Oncology Group (ECOG) 0-2.
- Absolute neutrophil count ≥ 0.75 × 10^9/L without granulocyte-colony-stimulating factor support, or ≥ 0.50 × 10^9/L in patients with documented bone marrow involvement considered to impair hematopoiesis. Granulocyte-colony-stimulating factor support is permitted in patients with documented bone marrow involvement.
- Hemoglobin ≥ 8 g/dL or ≥ 6 g/dL in patients with documented bone marrow involvement considered to impair hematopoiesis. Transfusion support is permitted in patients with bone marrow involvement.
- Platelets ≥ 50 × 10^9/L. If an investigator has chosen bendamustine/rituximab as the Arm B treatment, platelets must be ≥ 75 × 10^9/L. Patients may enroll below these thresholds if the Investigator determines the cytopenia is related to bone marrow involvement considered to impair hematopoiesis. Patients with a platelet count < 30 x 10^9/L are excluded.
- AST and ALT ≤ 3.0 x upper limit of normal (ULN).
- Total bilirubin ≤ 1.5 x ULN.
- Estimated creatinine clearance of ≥ 30 mL/min.
-
Known or suspected Richter's transformation at any time preceding enrollment.
-
Known or suspected history of central nervous system (CNS) involvement by CLL/SLL.
-
Ongoing drug-induced liver injury.
-
Active uncontrolled auto-immune cytopenia.
-
Significant cardiovascular disease.
-
History of allogeneic or stem cell transplantation (SCT) or chimeric antigen receptor-modified T cells (CAR-T) therapy within the past 60 days.
-
Active hepatitis B or hepatitis C.
-
Known active cytomegalovirus (CMV) infection.
-
Active uncontrolled systemic bacterial, viral, fungal or parasitic infection.
-
Known Human Immunodeficiency Virus (HIV) infection, regardless of CD4 count.
-
Clinically significant active malabsorption syndrome or inflammatory bowel disease
-
Prior exposure to non-covalent (reversible) BTK inhibitor.
-
Patients requiring therapeutic anticoagulation with warfarin or another Vitamin K antagonist.
-
Current treatment with strong cytochrome P450 (CYP) 3A4 (CYP3A4) inhibitors or inducers.
-
Vaccination with a live vaccine within 28 days prior to randomization.
-
Patients with the following hypersensitivity:
- Known hypersensitivity, including anaphylaxis, to any component or excipient of LOXO-305. For patients planned to receive idelalisib, known hypersensitivity, including anaphylaxis, to any component or excipient of idelalisib. For patients planned to receive bendamustine, known hypersensitivity, including anaphylaxis, to any component or excipient of bendamustine.
- Prior significant hypersensitivity to rituximab.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Arm A - Pirtobrutinib Pirtobrutinib Participants received 200 milligrams (mg) of pirtobrutinib administered orally once daily (QD) on Days 1 through 28 of a 28-day cycle. The treatment was continued until progressive disease, a discontinuation criterion, or unacceptable toxicity. Arm B - Idelalisib plus Rituximab or Bendamustine plus Rituximab Idelalisib Participants received either 150 mg of idelalisib administered twice-daily (BID) orally on Days 1 through 28 of a 28-day cycle in combination with 375 milligram per square meter (mg/m\^2) of rituximab by intravenous (IV) infusion on day 1 of cycle 1, then 4 IV infusions of rituximab 500 mg/m\^2 every 2 weeks (Q2W) and 3 IV infusions of rituximab 500 mg/m\^2 every 4 weeks (Q4W) or 70 mg/m\^2 of bendamustine administered IV on day 1 and 2 of each 28-day cycle from cycles 1 to 6 in combination with 375 mg/m\^2 of rituximab IV on day 1 of cycle 1, then 500 mg/m\^2 of rituximab on day 1 of each 28-day cycle from cycles 2 to 6. Arm B - Idelalisib plus Rituximab or Bendamustine plus Rituximab Bendamustine Participants received either 150 mg of idelalisib administered twice-daily (BID) orally on Days 1 through 28 of a 28-day cycle in combination with 375 milligram per square meter (mg/m\^2) of rituximab by intravenous (IV) infusion on day 1 of cycle 1, then 4 IV infusions of rituximab 500 mg/m\^2 every 2 weeks (Q2W) and 3 IV infusions of rituximab 500 mg/m\^2 every 4 weeks (Q4W) or 70 mg/m\^2 of bendamustine administered IV on day 1 and 2 of each 28-day cycle from cycles 1 to 6 in combination with 375 mg/m\^2 of rituximab IV on day 1 of cycle 1, then 500 mg/m\^2 of rituximab on day 1 of each 28-day cycle from cycles 2 to 6. Arm B - Idelalisib plus Rituximab or Bendamustine plus Rituximab Rituximab Participants received either 150 mg of idelalisib administered twice-daily (BID) orally on Days 1 through 28 of a 28-day cycle in combination with 375 milligram per square meter (mg/m\^2) of rituximab by intravenous (IV) infusion on day 1 of cycle 1, then 4 IV infusions of rituximab 500 mg/m\^2 every 2 weeks (Q2W) and 3 IV infusions of rituximab 500 mg/m\^2 every 4 weeks (Q4W) or 70 mg/m\^2 of bendamustine administered IV on day 1 and 2 of each 28-day cycle from cycles 1 to 6 in combination with 375 mg/m\^2 of rituximab IV on day 1 of cycle 1, then 500 mg/m\^2 of rituximab on day 1 of each 28-day cycle from cycles 2 to 6.
- Primary Outcome Measures
Name Time Method Progression-free Survival (PFS) Assessed by Independent Review Committee (IRC) Randomization to Disease Progression or Death Due to Any Cause (Up to 29 Months) PFS is defined as the time from the date of randomization to the date of first documentation of progressive disease (PD) or death from any cause, as evaluated by an IRC according to International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2018.
- Secondary Outcome Measures
Name Time Method PFS Assessed by Investigator Randomization to Disease Progression or Death Due to Any Cause (Up to 36 Months) PFS is defined as time from the date of randomization to the date of first documentation of PD or death from any cause, as evaluated by an investigator according to iwCLL 2018.
Overall Survival (OS) Randomization to Death from Any Cause (Up to 36 months) OS was defined as time from randomization to death due to any cause.
Time to Next Treatment (TTNT) Randomization to Subsequent Anticancer Therapy, Therapy of Pirtobrutinib or Death Due to Any Cause (Up to 36 Months) TTNT was defined as time from the date of randomization to the date of initiation of the subsequent anticancer therapy for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), therapy of pirtobrutinib for Arm B patients, or death due to any cause, whichever occurs first.
Event Free Survival (EFS) Randomization to Disease Progression, Subsequent Anticancer Therapy, Unacceptable Toxicity Leading to Treatment Discontinuation, or Death Due to Any Cause (Up to 36 Months) EFS is defined as the time from randomization to the first occurrence of:
* Documented disease progression per iwCLL 2018 criteria as assessed by Investigator; or
* Initiation of subsequent anticancer therapy for CLL/SLL; or
* Unacceptable toxicity leading to treatment discontinuation as assessed by the Investigator; or
* Death (due to any cause).Percentage of Participants With Overall Response Rate (ORR) Assessed by Investigator Randomization to Subsequent Anticancer Therapy, Disease Progression or Death Due to Any Cause (Up to 36 Months) ORR according to investigator-assessed best overall response (BOR) based on iwCLL 2018 is defined as the number of participants who achieve a BOR of complete response (CR), complete response with incomplete bone marrow recovery (CRi), nodular partial response (nPR) or partial response (PR) at or before the initiation of subsequent anticancer therapy divided by the total number of participants randomized to each treatment arm.
Time to Worsening (TTW) of CLL/SLL Related Symptoms Baseline up to Week 25 (Arm A and Arm B - Idelalisib plus Rituximab) & Baseline up to Week 21 + Safety Follow-Up of up to 5 Weeks (Arm B - Bendamustine plus Rituximab) TTW was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms.
The time to sustained patient-reported outcome (PRO) deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A \& Arm B - Idelalisib plus Rituximab) and up to Week 21 + Safety follow-up of up to 5 weeks (Arm B - Bendamustine plus Rituximab) assessment time point prior to disease progression.Time to Worsening (TTW) of Physical Function Baseline up to Week 25 (Arm A and Arm B - Idelalisib plus Rituximab) & Baseline up to Week 21 + Safety Follow-Up of up to 5 Weeks (Arm B - Bendamustine plus Rituximab) Time of worsening was defined as a change in score greater than the meaningful within-person change for worsening in score. Scores were furthermore required to be sustained. To meet the requirement for sustained change, the assessment following the first observation of a meaningful worsening of the score (event date) was also required to show a meaningful worsening compared to baseline. The event date was defined as the first of these consecutive events. The European Organization for Research and Treatment of Cancer Item Library 87 was used, which is scored from 0-100, with higher scores reflecting more symptoms.
The time to sustained PRO deterioration was calculated using all on-treatment assessment time points up to the Week 25 (Arm A and IdelaR) and up to Week 21 + Safety follow-up (BR) assessment time point prior to disease progression.
Trial Locations
- Locations (232)
Princess Margaret Hospital (Ontario)
🇨🇦Toronto, Ontario, Canada
Community Health Network
🇺🇸Indianapolis, Indiana, United States
Southern Medical University Nanfang Hospital
🇨🇳Guangzhou, Guangdong, China
The Affiliated Hospital of Xuzhou Medical College
🇨🇳Xuzhou, Jiangsu, China
The Second Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Tianjin Medical University Cancer Institute and Hospital
🇨🇳Tianjin, Tianjin, China
Affiliated Tumor Hospital of Xinjiang Medical University
🇨🇳Ürümqi, Xinjiang, China
Blood Institute of the Chinese Academy of Medical science
🇨🇳Tianjin, China
Lübecker Onkologische Schwerpunktpraxis
🇩🇪Lübeck, Schleswig-Holstein, Germany
Centre de Lutte Contre le Cancer - Centre Henri Becquerel Normandie Rouen
🇫🇷Rouen, Seine-Maritime, France
Irccs Crob
🇮🇹Rionero In Vulture, Potenza, Italy
SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
🇭🇺Nyiregyhaza, Hungary
Uniwersytecki Szpital Kliniczny Klinika
🇵🇱Wrocław, Poland
Clinica di Ematologia IOSI, Ospedale Bellinzona e Valli, Ente Ospedaliero Cantonale
🇨🇭Bellinzona, Svizzera, Switzerland
The Royal Cornwall Hospital
🇬🇧Truro, Cornwall, United Kingdom
Japanese Foundation for Cancer Research
🇯🇵Koto, Tokyo, Japan
Uniwersyteckie Centrum Kliniczne
🇵🇱Gdansk, Pomorskie, Poland
Tri-Service General Hospital
🇨🇳Taipei City, Taipei, Taiwan
Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza
🇵🇱Brzozów, Poland
Norfolk and Norwich Hospital
🇬🇧Norwich, Norfolk, United Kingdom
Western General Hospital
🇬🇧Edinburgh, Scotland, United Kingdom
Royal Marsden Hospital
🇬🇧Sutton, Surrey, United Kingdom
St Johns Hospital at Howden
🇬🇧Livingston, West Lothian, United Kingdom
Fakultni nemocnice Brno
🇨🇿Brno, Czechia
München Klinik Schwabing
🇩🇪Koelner Platz 1, München, Germany
Beaumont Hospital, Dublin
🇮🇪Dublin, Ireland
Boca Raton Regional Hospital
🇺🇸Boca Raton, Florida, United States
Palo Verde Hematology Oncology
🇺🇸Glendale, Arizona, United States
Orange Coast Memorial Medical Center
🇺🇸Fountain Valley, California, United States
Arizona Oncology Associates, P.C. - HOPE
🇺🇸Tucson, Arizona, United States
California Research Institute
🇺🇸Los Angeles, California, United States
Southern Cancer Center, P.C.
🇺🇸Daphne, Alabama, United States
Mitchell Cancer Institute -University of South Alabama
🇺🇸Mobile, Alabama, United States
WellStar Health System
🇺🇸Marietta, Georgia, United States
Cancer Specialists of North Florida -St Augustine
🇺🇸Jacksonville, Florida, United States
Medizinische Universität Wien
🇦🇹Wien, Austria
Arnett Cancer Center
🇺🇸Lafayette, Indiana, United States
Texas Oncology - Medical City Dallas
🇺🇸Dallas, Texas, United States
Universitair Ziekenhuis Gent
🇧🇪Gent, Belgium
Nebraska Hematology-Oncology
🇺🇸Lincoln, Nebraska, United States
Oncology Hematology Care Inc
🇺🇸Cincinnati, Ohio, United States
Peking University Third Hospital
🇨🇳Beijing, Beijing, China
Uniklinikum Salzburg
🇦🇹Salzburg, Osterreich, Austria
Greenebaum Comprehensive Cancer Center
🇺🇸Baltimore, Maryland, United States
Texas Oncology - San Antonio Medical Center
🇺🇸San Antonio, Texas, United States
VITAZ
🇧🇪Sint-Niklaas, Oost-Vlaanderen, Belgium
Clinique Saint Pierre Ottignies
🇧🇪Ottignies, Belgium
University of Kentucky Markey Cancer Center
🇺🇸Lexington, Kentucky, United States
Zhejiang Provincial Taizhou Hospital
🇨🇳Linhai, Zhejiang, China
Centre Hospitalier Lyon Sud
🇫🇷Pierre Benite, Cedex, France
Texas Oncology - Amarillo
🇺🇸Amarillo, Texas, United States
The Center for Cancer and Blood Disorders
🇺🇸Fort Worth, Texas, United States
Canberra Hospital
🇦🇺Garran, Australian Capital Territory, Australia
New Jersey Center for Cancer Research
🇺🇸Brick, New Jersey, United States
Ascension St. John Hospital
🇺🇸Grosse Pointe Woods, Michigan, United States
Ordensklinikum Linz GmbH Elisabethinen
🇦🇹Linz, Oberösterreich, Austria
Universitätsklinikum Schleswig-Holstein
🇩🇪Kiel, Schleswig-Holstein, Germany
Fudan University Shanghai Cancer Center
🇨🇳Shanghai, China
Mercy Health-Paducah Medical Oncology and Hematology
🇺🇸Paducah, Kentucky, United States
ASST Spedali Civili - Università degli Studi
🇮🇹Brescia, Italy
University of Wisconsin Carbone Cancer Center
🇺🇸Madison, Wisconsin, United States
Carmel Hospital
🇮🇱Haifa, Ḥeifā, Israel
Minnesota Oncology/Hematology PA
🇺🇸Saint Paul, Minnesota, United States
St. Vincent Frontier Cancer Center
🇺🇸Billings, Montana, United States
Brooke Army Medical Center
🇺🇸Fort Sam Houston, Texas, United States
Ch Perpignan
🇫🇷Perpignan, France
CHR Verviers-Onco
🇧🇪Verviers, Liege, Belgium
AZ Delta
🇧🇪Roeselare, West Flanders, Belgium
Memorial Sloan Kettering Cancer Center
🇺🇸New York, New York, United States
Groupe Jolimont
🇧🇪Haine-Saint-Paul, Belgium
Cancer Center Office of Clinical Research
🇺🇸New Orleans, Louisiana, United States
AZ St-Elisabeth
🇧🇪Herentals, Belgium
Beijing Hospital
🇨🇳Beijing, China
Willamette Valley Cancer Institute and Research Center
🇺🇸Eugene, Oregon, United States
Xuanwu Hospital Capital Medical University
🇨🇳Xicheng District, Beijing, China
Gansu Province Cancer Hospital
🇨🇳Lanzhou, Gansu, China
Texas Oncology - Dallas Presbyterian Hospital
🇺🇸Dallas, Texas, United States
Carolina Blood and Cancer Care Associates
🇺🇸Rock Hill, South Carolina, United States
Virginia Cancer Specialists, PC
🇺🇸Gainesville, Virginia, United States
Ingham Institute of Medical Research
🇦🇺Liverpool, New South Wales, Australia
Saint Joseph Mercy Hospital
🇺🇸Ann Arbor, Michigan, United States
University of Rochester
🇺🇸Rochester, New York, United States
Texas Oncology Fort Worth
🇺🇸Fort Worth, Texas, United States
Westmead Hospital
🇦🇺Wentworthville, New South Wales, Australia
Hunan Cancer Hospital
🇨🇳Changsha, Hunan, China
Queen Elizabeth II Health Sciences Center
🇨🇦Halifax, Nova Scotia, Canada
Hainan Province People's Hospital
🇨🇳Haikou, Hainan, China
Shanghai Jiaotong University School of Medicine Ruijin Hospital
🇨🇳Shanghai, China
Uniklinik Köln
🇩🇪Kerpener, Köln, Germany
Sun Yat-sen University Cancer Center
🇨🇳Guangzhou, Guangdong, China
Zhejiang Cancer Hospital
🇨🇳Hangzhou, Zhejiang, China
University of Pecs 1st. Internalmedicin Clinic Dept
🇭🇺Pecs, Hungary
Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
🇭🇺Budapest, Hungary
Azienda Ospedaliera Nazionale Santi Antonio e Biagio e Cesare Arrigo
🇮🇹Alessandria, Italy
Ospedale Papardo
🇮🇹Messina, Italy
CHRU de Brest - Hôpital Morvan
🇫🇷Brest cedex, France
Rabin Medical Center
🇮🇱Petah Tikva, HaMerkaz, Israel
Universitätsmedizin Mainz III. Medizinische Klinik und Poliklinik
🇩🇪Langenbeckstraße 1, Mainz, Germany
Fakultni nemocnice Hradec Kralove
🇨🇿Hradec Kralove, Czechia
Hopital Saint Vincent De Paul
🇫🇷Lille cedex, France
Universitätsklinikum Heidelberg
🇩🇪Heidelberg, Baden-Württemberg, Germany
Pole Regionalde Cancérologie(CHU de Poitiers)
🇫🇷Politiers, France
Mater Misericordiae Hospital
🇮🇪Dublin 7, Ireland
St James's Hosptial
🇮🇪Dublin 8, Ireland
Oddzial Hematologiczny, Specjalistyczny Szpital im. dra Sokołowskiego w Wałbrzychu
🇵🇱Walbrzych, Poland
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy
🇵🇱Warszawa, Poland
Kochi Medical School Hospital
🇯🇵Nankoku, Kochi, Japan
Pusan National University Hospital
🇰🇷Busan, Pusan-Kwangyǒkshi, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Seoul-teukbyeolsi [Seoul], Korea, Republic of
Hospital Universitario Virgen del Rocío
🇪🇸Sevilla, Spain
Gleneagles Medical Centre
🇸🇬Singapore, Central Singapore, Singapore
Szpital Uniwersytecki nr 2 im. dr Jana Biziela w BydgoszczyKlinika Hematologii
🇵🇱Bydgoszcz, Poland
NTT Medical Center Tokyo
🇯🇵Shinagawa-Ku, Tokyo, Japan
Taipei Veterans General Hospital
🇨🇳Taipei City, Taiwan
Ogaki Municipal Hospital
🇯🇵Ogaki-shi, Gifu, Japan
JCHO Kyushu Hospital
🇯🇵Fukoka-ken, Japan
Kindai University Hospital
🇯🇵Osaka Sayama-shi, Osaka, Japan
Hospital Universitario Infanta Leonor-INTERNAL MED
🇪🇸Madrid, Spain
Pratia MCM Krakow
🇵🇱Krakow, Poland
The Catholic University of Korea-Seoul St. Mary's Hospital
🇰🇷Seocho-Gu, Seoul, Korea, Republic of
Nagoya Medical Center
🇯🇵Nagoya, Aichi, Japan
Aichi Cancer Center Hospital
🇯🇵Nagoya, Aichi, Japan
Gachon University Gil Hospital
🇰🇷Namdong-gu, Incheon-gwangyeoksi [Incheon], Korea, Republic of
NHO Sendai Medical Center
🇯🇵Sendai-shi, Miyagi-Ken, Japan
Inje Univ Busan Paik Hospital
🇰🇷Busan, Korea, Republic of
Centrum Onkologii Ziemi Lubelskiej
🇵🇱Lublin, Lubelskie, Poland
Okayama University Hospital
🇯🇵Okayama, Japan
Szpitale Pomorskie Sp. z o. o.
🇵🇱Gdynia, Pomorskie, Poland
Pratia Onkologia Katowice
🇵🇱Katowice, Poland
Instytut Hematologii i Transfuzjologii
🇵🇱Warszawa, Poland
Federal State Budgetary Institution "Russian Scientific and Research Institute of Hematology and Transfusiology of Federal Medico-Biological Agency
🇷🇺Saint Petersburg, Russian Federation
Chang Gung Memorial Hospital - Linkou
🇨🇳Taoyuan, (r.o.c.), Taiwan
Istanbul University Istanbul Medicine Faculty
🇹🇷Faith, Istanbul, Turkey
Gazi University Faculty of Medicine
🇹🇷Ankara, Yenimahalle, Turkey
Derriford Hospital
🇬🇧Plymouth, Devon, United Kingdom
Erciyes University Faculty of Medicine
🇹🇷Kayseri, Melikgazi, Turkey
Hospital General de Albacete
🇪🇸Albacete, Spain
China Medical University Hospital
🇨🇳Taichung City, Taichung, Taiwan
Ege University Medical Faculty
🇹🇷Izmir, Turkey
Azienda Ospedaliera Pugliese Ciaccio
🇮🇹Catanzaro, Italy
AULSS8 Berica-Ospedale S.Bortolo
🇮🇹Vicenza, Veneto, Italy
Irccs Istituto Tumori Giovanni Paolo Ii
🇮🇹Viale Orazio Flacco, Bari, Italy
ASST-Monza -U.O Ematologia Adulti
🇮🇹Monza (MB) -Settore E, Piano 2, Italy
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
🇮🇹Bergamo, Italy
A.O.U. Policlinico G.Rodolico - S. Marco
🇮🇹Catania, Italy
Azienda Ospedaliera Universitaria Careggi
🇮🇹Firenze, Italy
ASST Grande Ospedale Metropolitano Niguarda Comitato Etico Milano Area C
🇮🇹Milano, Italy
A.O.U. di Modena
🇮🇹Modena, Italy
Fondazione IRCCS Policlinico San Matteo
🇮🇹Pavia, Italy
Istituto di Ematologia-C.R.E.O. (Centro di Ricerche Emato-Oncologich)
🇮🇹Perugia, Italy
Az. Osp. "Card G Panico"
🇮🇹Tricase, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore
🇮🇹Roma, Italy
Azienda Sanitaria Universitaria Giuliano Isontina
🇮🇹Trieste, Italy
Centre Hospitalier de la Côte Basque
🇫🇷Bayonne, France
Nagoya City University Hospital
🇯🇵Nagoya, Aichi, Japan
Kumamoto University Hospital
🇯🇵Kumamoto, Japan
Osaka University Hospital
🇯🇵Osaka, Japan
Tohoku University Hospital
🇯🇵Sendai-shi, Miyagi, Japan
University College London Hospitals
🇬🇧London, Greater London, United Kingdom
GenesisCare Cambridge
🇬🇧Newmarket, United Kingdom
Hospital San Pedro de Alcántara
🇪🇸Caceres, Spain
Hospital General Universitario Gregorio Marañón
🇪🇸Madrid, Planta Baja, Spain
Hospital Universitario La Paz
🇪🇸Madrid, Spain
Hospital Universitario Marques De Valdecilla
🇪🇸Santander, Spain
Hospital Universitario de Alava
🇪🇸Vitoria, Spain
Illinois Cancer Specialists-Niles
🇺🇸Niles, Illinois, United States
Oncology and Hematology Associates of Southwest Virginia Inc
🇺🇸Roanoke, Virginia, United States
Cancer Care Manitoba
🇨🇦Winnipeg, Manitoba, Canada
St Vincent's Hospital
🇦🇺Darlinghurst, New South Wales, Australia
Oncology-Hematology Associates of West Broward
🇺🇸Tamarac, Florida, United States
Rush University Medical Center
🇺🇸Chicago, Illinois, United States
Norton Cancer Institute
🇺🇸Louisville, Kentucky, United States
Northwest Medical Specialties, PLLC
🇺🇸Tacoma, Washington, United States
Texas Oncology - McAllen
🇺🇸McAllen, Texas, United States
The St. George Hospital
🇦🇺Kogarah, New South Wales, Australia
The Alfred Hospital
🇦🇺Melbourne, Victoria, Australia
Kobe City Medical Center General Hospital
🇯🇵Kobe, Hyogo, Japan
Southlake Regional Health Centre
🇨🇦Newmarket, Ontario, Canada
CHU De Grenoble Hopital Albert Michallon
🇫🇷Grenoble, Cedex 09, France
Universitätsklinikum Ulm
🇩🇪Ulm, Baden-Württemberg, Germany
Hospital AVICENNE
🇫🇷Bobigny, Cedex, France
Centre Hospitalier du Mans
🇫🇷Le Mans, France
Hospital Clinic de Barcelona
🇪🇸Barcelona, Spain
Medical Oncology Hematology Consultants, PA
🇺🇸Newark, Delaware, United States
Rocky Mountain Cancer Center
🇺🇸Aurora, Colorado, United States
The First Affiliated Hospital of Nanchang University
🇨🇳Nanchang, Jiangxi, China
Henan Cancer Hospital
🇨🇳Zhengzhou, Henan, China
University Hospital Split
🇭🇷Split, Croatia
Division of Hematology, Dept. of Internal Medicine, University Hospital Centre Zagreb
🇭🇷Zagreb, Croatia
Vseobecna fakultni nemocnice v Praze
🇨🇿Praha 2, Czechia
CHD Vendee
🇫🇷La Roche-sur-Yon, La Roche Sur Yon, France
Chu Nimes/Institut De Cancerologie Du Gard
🇫🇷Nîmes, Nimes, France
Institut Bergonié - Centre Régional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest
🇫🇷Bordeaux, France
CHRU De Tours
🇫🇷Tours, Tours Cedex 9, France
Charité Campus Virchow-Klinikum
🇩🇪Berlin, Germany
Debreceni Egyetem Klinikai Kozpont
🇭🇺Debrecen, Hungary
Laniado Medical Center
🇮🇱Netanya, Israel
Tel Aviv Sourasky Medical Center
🇮🇱Tel Aviv, Israel
Azienda Ospedaliero Universitaria Pisana
🇮🇹Pisa, PI, Italy
Soroka Medical Center
🇮🇱Beer Sheva, Israel
IRCCS Ospedale Policlinico San Martino
🇮🇹Genova, Italy
IRCCS Ospedale San Raffaele
🇮🇹Milano, Italy
Ospedale Santa Maria delle Croci
🇮🇹Ravenna, Italy
Azienda Ospedaliera Santa Maria Terni
🇮🇹Terni, Italy
A.O.U. Citta' della Salute e della Scienza di Torino
🇮🇹Torino, Italy
Ospedale Policlinico Giambattista Rossi, Borgo Roma
🇮🇹Verona, Italy
Hokkaido University Hospital
🇯🇵Sapporo, Hokkaido, Japan
Tokai University Hospital- Isehara Campus
🇯🇵Isehara, Kanagawa, Japan
Saitama Medical Center
🇯🇵Kawagoe, Saitama, Japan
Seoul National University Hospital
🇰🇷Seoul, Seoul, Korea, Korea, Republic of
Wojewodzki Szpital Specjalistyczny
🇵🇱Iwaszkiewicza 5, Legnica, Poland
Budgetary Healthcare Institution of Omsk Region "Clinical Oncology Dispensary"
🇷🇺Omsk, Omskaya Oblast', Russian Federation
Wojewódzkie Wielospecjalistyczne Centrum Onkologii i Traumatologii
🇵🇱Łódź, Poland
Academician I.P. Pavlov First St-Petersburg State Medical University
🇷🇺Saint Petersburg, Russian Federation
Oncology Dispensary #2 of Krasnodar Region
🇷🇺Sochi, Russian Federation
Hospital Duran I Reynals
🇪🇸Hospitalet De Llobregat, Barcelona, Spain
Hospital Universitario de Toledo
🇪🇸Toledo, Castilla La Mancha, Spain
Complejo Hospitalario Universitario de Santiago de Compostel
🇪🇸Santiago de Compostela, La Coruna, Spain
Hospital Universitario Quironsalud Madrid
🇪🇸Pozuelo De Alarcón, Madrid, Spain
Hospital Universitario Ramon y Cajal
🇪🇸Madrid, Madrid, Comunidad De, Spain
Hospital Universitari Vall d'Hebron
🇪🇸Barcelona, Spain
Ankara University Medicine Hospital
🇹🇷Mamak, Ankara, Turkey
Aberdeen Royal Infirmary
🇬🇧Aberdeen, Aberdeen City, United Kingdom
Dokuz Eylul University Faculty of Medicine
🇹🇷Izmir, Turkey
Singleton Hospital
🇬🇧Swansea, Sa2 8qa, United Kingdom
St James's University Hospital
🇬🇧Leeds, United Kingdom
Milton Keynes University Hospital
🇬🇧Milton Keynes, United Kingdom
Texas Oncology Cancer Center
🇺🇸Austin, Texas, United States
Clinical Research Alliance, Inc.
🇺🇸Westbury, New York, United States
Royal Perth Hospital
🇦🇺Perth, Western Australia, Australia
Castle Hill Hospital
🇬🇧Cottingham, East Yorkshire, United Kingdom
Peking University First Hospital
🇨🇳Beijing, Beijing, China